Vaxxinity, Inc. VAXX
0.00
0.00
NaN
as of 25 Sep
- Market cap
- $15.5M
- P/E
- 0.0×
Follow VAXX
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | |
|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 | — | — |
P/S ratio |
— | — | 1,822.86 | 2,347.83 | — | — |
P/FCF ratio |
— | — | 0.00 | 0.00 | — | — |
P/Operating CF |
— | — | (53.97) | (30.77) | — | — |
P/B ratio |
— | — | 0.00 | 3.34 | — | — |
Price to Tangible BV |
— | — | 0.00 | 3.72 | — | — |
EV/Sales |
— | — | 1,696.24 | 1,611.58 | — | — |
EV/EBITDA |
— | — | 0.00 | 0.00 | — | — |
EV/Operating CF |
— | — | (13.52) | (3.64) | — | — |
EV/FCF |
— | — | (13.26) | (3.56) | — | — |
Quick Ratio |
— | 0.04 | 0.79 | 5.29 | 2.86 | 1.73 |
Current Ratio |
— | 0.07 | 0.91 | 5.61 | 3.03 | 1.89 |
Net Debt/EBITDA |
— | (0.05) | 0.65 | 1.09 | 0.99 | 0.30 |
Debt/Assets |
0.00% | 70.47% | 21.34% | 6.19% | 12.26% | 29.93% |
Debt/Equity |
— | (0.02) | (0.12) | 0.08 | 0.21 | 0.99 |
Asset Turnover |
— | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.86 | 0.85 | 0.59 | 0.74 | 1.01 |
Capex/Depreciation |
— | 0.00 | (1.79) | (0.97) | (2.61) | (1.10) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 20.93% | 58.81% | (665.19%) | (78.85%) | (150.65%) | |
| — | (1,782.95%) | (154.46%) | (126.54%) | (55.09%) | (75.55%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 77.78% | (471.52%) | (98.56%) | (99.69%) | (213.19%) |
Average Days of Receivables |
— | 0.00 | 17.04 | 2,173.41 | 0.00 | — |
Research and Development Expense of Revenue |
— | 0.00% | 3,693.00% | 108,150.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 2,193.36% | 78,522.73% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 182.05% | 46,078.79% | 0.00% | 0.00% |
Graham Net Nets |
— | — | (0.17) | 0.27 | — | — |
Graham Number |
— | — | 0.00 | 0.00 | — | — |
Earnings Yield |
— | — | (9.31%) | (31.71%) | — | — |
Free Cash Flow Yield |
— | — | (7.02%) | (19.28%) | — | — |
Revenue per Share |
— | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.36) | (0.52) | (1.06) | (0.44) | (0.45) |
Capex per Share |
— | 0.00 | (0.02) | (0.02) | (0.01) | (0.01) |
Free Cash Flow per Share |
— | (0.36) | (0.54) | (1.07) | (0.46) | (0.46) |
Cash per Share |
— | 0.01 | 0.47 | 1.89 | 0.70 | 0.24 |
Shareholders Equity per Share |
— | (1.42) | (1.33) | 1.68 | 0.49 | 0.11 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (1.42) | (1.33) | 1.68 | 0.49 | 0.11 |
Free Cash Flow |
— | (12.26) | (35.39) | (82.31) | (57.79) | (58.04) |
Working Capital |
— | (18.44) | (3.68) | 126.81 | 62.95 | 15.63 |
Capital Expenditures |
— | — | (1.48) | (1.32) | (1.87) | (0.80) |
Net Current Asset Value |
— | (48.67) | (101.84) | 116.25 | 49.67 | 2.33 |
EV/EBIT |
— | — | 0.00 | 0.00 | — | — |
Capex to Sales |
— | — | 2.65 | 19.97 | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | (7,173.61%) | (207,840.91%) | 0.00% | 0.00% |
Price to Operating Income |
— | — | 0.00 | 0.00 | — | — |
| Other line items | ||||||
Depreciation/Fixed assets |
— | 0.67 | 0.07 | 0.11 | 0.06 | 0.07 |
Cash ROIC |
— | 26.49% | 101.17% | (32.87%) | (41.95%) | (119.50%) |
Accounts Receivable Turnover |
— | 0.00 | 3.39 | 0.32 | 0.00 | — |
Accounts Payable Turnover |
— | 0.01 | 0.05 | 0.92 | 0.40 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
— | 4,380.00 | 7,138.56 | 601.49 | 1,147.67 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
— | 0.35 | 0.16 | 0.21 | 0.55 | — |
Average Payables |
— | 7.69 | 1.15 | 2.10 | 4.24 | 3.54 |
Average Assets |
— | 0.80 | 25.87 | 108.41 | 136.54 | 75.36 |
Average Common Equity |
— | (67.94) | (67.94) | 20.62 | 95.40 | 37.79 |
Columns are period end dates